Chemoradiotherapy for Muscle-invasive Bladder Cancer; 5-year Survival Outcomes, the Edinburgh Cancer Centre Experience

Purpose: Muscle-invasive bladder cancer (MIBC) constitutes about 30% of newly diagnosed bladder cancers. Only approximately 45% of patients survive for 5 years regardless of the type of treatment they receive [1]. Radical cystectomy has previously been considered standard therapy for MIBC. More recently, concurrent chemoradiotherapy (CRT) has emerged as an alternative treatment option [2]. A retrospective audit was carried out to review recurrence and survival rates amongst patients with MIBC treated with CRT at the Edinburgh Cancer Centre.

Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: J. Parry, E. Doyle, O. Curran, A. Law, D. McLaren, J. Malik Source Type: research